Manual screening can quietly become one of the biggest…
Manual screening can quietly become one of the biggest risks in oncology trial recruitment. Oncology studies are complex by nature. Eligibility criteria can…
Trial Watch posts – May 2026
Public Trial Watch posts from May 2026, newest first. Each heading links to the post.
Global Rise of Compounded Weight-Loss Medicines: A…
The rise of compounded weight-loss drugs has emerged as a pressing global health issue, threatening consumers and health-care systems. Factors fueling this…
Radiopharmaceuticals are reshaping what precision medicine…
Radiopharmaceuticals are reshaping what precision medicine can mean. Instead of treating disease only by location or broad category, radiopharmaceuticals…
At Faces of Research, Brent Clary, CCRC, Principal…
At Faces of Research, Brent Clary, CCRC, Principal Clinical Trials Manager at J & S Studies, shares what clinical research looks like beyond protocols, data…
Early phase trials are no longer just early scientific…
Early phase trials are no longer just early scientific experiments. They are becoming some of the most important signals for clinical trial design risk. What…
Trial Watch: May Edition 9
Where competition is sharpening in real time · The first half of May 2026 shows one clear pattern. Clinical development is moving into sharper, more…
AI in clinical trials is no longer just a future…
AI in clinical trials is no longer just a future conversation. It is already shaping how sponsors, CROs and sites think about protocol design, site selection…
International Clinical Trial Day reminds us that clinical…
International Clinical Trial Day reminds us that clinical research has always been a journey of courage, ethics and progress. From James Lind’s first clinical…
GLP 1 therapies have changed the way obesity treatment is…
GLP 1 therapies have changed the way obesity treatment is being understood. What began as a breakthrough in metabolic care has now created a new challenge for…
At Faces of Research, Sherice Dove, CCRC from Durham…
At Faces of Research, Sherice Dove, CCRC from Durham Nephrology Associates shares insights into the evolving landscape of nephrology research and the growing…
At Faces of Research, Pam Lightfield from Eye Centers of…
At Faces of Research, Pam Lightfield from Eye Centers of Racine and Kenosha shares insights into the evolving landscape of ophthalmology research and the…
Trial Watch Edition 4 is live.
Trial Watch Edition 4 is live. This edition tracks high signal clinical trial activity from February 1 to February 15, 2026, across oncology, cardiometabolic…
Trial Watch: April Edition 7
Clinical trial research intelligence across focused therapeutic areas · Trial Watch Edition 7 tracks 9 clinical trial signals across 4 therapy areas, based on…
Clinical development times for innovative drugs
New drug development is a race against the clock as soon as the first patents are filed, and understanding the potential timings from first-in-human studies…
Trial Watch: April Edition 8
Where conviction is building in real time · The second half of April 2026 shows three clear signals. Oncology programs are moving into direct competitive…
Trial Watch Edition 7 tracks clinical trial activity from…
Trial Watch Edition 7 tracks clinical trial activity from April 1 to April 15, 2026, with signals across oncology, cardiometabolic, immunology, and neurology…
Trial Watch 8: Oncology pipelines are entering direct…
Cell therapy programs are rapidly moving beyond early validation into direct positioning battles across autoimmune and oncology indications. · Oncology…
Trial Watch 8: Immunology programs are moving into direct…
Sponsors are increasingly testing immune mediated disease assets against existing standards rather than relying only on isolated efficacy studies. ·…
Psilocybin, an Effective Treatment for Major Depressive…
Psilocybin is a classical psychedelic which has been utilised for healing purposes for millenia. However, with its classification as a Schedule I substance…
Trial Watch Edition 9 is live.
Trial Watch Edition 9 is live. This edition tracks 15 high signal clinical trial events from May 1 to May 15, 2026, across oncology, cardiometabolic disease…
The first kits !!!